Astex Pharmaceuticals is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.
• Robust proprietary oncology portfolio with multiple drugs in mid-late stage clinical development
• Developing CNS portfolio of novel targeted therapeutics for defined neurodegenerative disease populations
• Productive partnerships with top-tier pharmaceutical companies • Visionary leadership backed by a world-class management team • Oncology and CNS Focused
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and diseases of the CNS. Astex is developing a proprietary pipeline of novel targeted therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. In October 2013 Astex became a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan.
The Otsuka Group employs approximately 43,000 people globally, and its products are available in more than 80 countries worldwide. For more information about Otsuka Pharmaceutical please visit www.otsuka.com/en/